FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588227109> ?p ?o ?g. }

• W2588227109 abstract "Abstract Abstract 3224 Background: Methotrexate (MTX), both intrathecal (IT) and intravenous (IV) may induce acute neurotoxicity, typically manifested as seizures or stroke-like encephalopathy. The FRALLE 93 trial reported exposure to high-dose (HD) MTX as an independent risk factor for acute neurotoxicity in univariate analysis 1. Pediatric Oncology Group (POG) trial 9005 showed an association between IV MTX and acute neurotoxicity2. We investigate risk factors associated with acute neurotoxicity in children treated according to recent Children's Oncology Group (COG)-modified Berlin-Frankfurt-Munster (BFM)-based protocols, specifically whether number of doses of IT MTX therapy given during delayed intensification (DI) is an independent predictor. Patients and Methods: A retrospective cohort of 167 children ages 1–21 years with ALL treated at our institution according to COG-modified BFM-based therapy between January 2001 and December 2007 with complete records available were reviewed. Patients who received bone marrow transplant in first remission or died prior to DI were excluded. In patients who relapsed, only data regarding therapy prior to relapse was reviewed. Baseline characteristics between patients with acute neurotoxicity (n= 11) and patients without acute neurotoxicity (n= 156) were assessed for differences using the two-tailed student's t-test for continuous variables and the Chi-squared test or Fisher's exact test for categorical variables. Logistical regression analysis was performed using age, diagnosis (pre-B versus T-cell ALL), administration of HD MTX, administration of cranial irradiation (cXRT) and doses of IT MTX (two, on days 1/29, vs. three, on days 1/29/36) administered during DI as predictor variables. Interaction between doses of IT MTX and administration of HD MTX or cXRT was not able to be reliably assessed because of the rarity of the outcome event. Results: 4/136 (3%) patients who received two doses of IT MTX during DI experienced acute neurotoxicity either during DI or thereafter compared with 7/31 (23%) patients who received three doses of IT MTX (p = 0.0008). Univariate analysis showed no significant differences in diagnosis, administration of HD MTX, cranial radiation and relapse rate between patients with acute neurotoxicity vs. those without. Patients with acute neurotoxicity were more likely to be older (p = 0.05) and have received three doses of IT MTX during DI than patients without an event (see table). In multivariate analysis, patients who received three doses of IT MTX during DI were at increased risk of acute neurotoxicity (OR = 7.6, 95% confidence interval 1.7–33.7) adjusted for age, diagnosis, administration of HD MTX and cXRT. Older age was no longer a significant predictor of acute neurotoxicity (OR = 1.1, 95% confidence interval 0.94–1.3). Conclusion: In children with ALL treated per COG-modified BFM-based protocols at our institution, three doses of IT MTX during DI (Days 1/29/36) was associated with a higher risk for acute neurotoxicity compared to two IT MTX doses on Days 1/29. The association between Day 36 IT MTX and acute neurotoxicity was seen in both univariate and multivariate analysis adjusted for age, diagnosis, administration of HD MTX and cXRT. This association should be explored in a larger patient cohort, and if confirmed, warrants consideration of eliminating IT MTX on Day 36 of DI. 1. Dufourg NM et al. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 2007; 21:238-47. 2. Mahoney DH et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy – a Pediatric Oncology Group study. J Clin Oncol 1998; 16:1712-22. Disclosures: No relevant conflicts of interest to declare." @default.
• W2588227109 created "2017-02-24" @default.
• W2588227109 creator A5042457425 @default.
• W2588227109 creator A5050107389 @default.
• W2588227109 creator A5060453219 @default.
• W2588227109 date "2010-11-19" @default.
• W2588227109 modified "2023-10-01" @default.
• W2588227109 title "Acute Neurotoxicity In Children with Acute Lymphoblastic Leukemia: An Association with Day-36 Intrathecal Methotrexate In Delayed Intensification" @default.
• W2588227109 doi "https://doi.org/10.1182/blood.v116.21.3224.3224" @default.
• W2588227109 hasPublicationYear "2010" @default.
• W2588227109 type Work @default.
• W2588227109 sameAs 2588227109 @default.
• W2588227109 citedByCount "0" @default.
• W2588227109 crossrefType "journal-article" @default.
• W2588227109 hasAuthorship W2588227109A5042457425 @default.
• W2588227109 hasAuthorship W2588227109A5050107389 @default.
• W2588227109 hasAuthorship W2588227109A5060453219 @default.
• W2588227109 hasConcept C126322002 @default.
• W2588227109 hasConcept C144301174 @default.
• W2588227109 hasConcept C167135981 @default.
• W2588227109 hasConcept C187212893 @default.
• W2588227109 hasConcept C191093355 @default.
• W2588227109 hasConcept C2776694085 @default.
• W2588227109 hasConcept C2776755627 @default.
• W2588227109 hasConcept C2778461978 @default.
• W2588227109 hasConcept C2779429289 @default.
• W2588227109 hasConcept C2779491297 @default.
• W2588227109 hasConcept C2781059491 @default.
• W2588227109 hasConcept C2781107101 @default.
• W2588227109 hasConcept C2909962599 @default.
• W2588227109 hasConcept C29730261 @default.
• W2588227109 hasConcept C38180746 @default.
• W2588227109 hasConcept C71924100 @default.
• W2588227109 hasConceptScore W2588227109C126322002 @default.
• W2588227109 hasConceptScore W2588227109C144301174 @default.
• W2588227109 hasConceptScore W2588227109C167135981 @default.
• W2588227109 hasConceptScore W2588227109C187212893 @default.
• W2588227109 hasConceptScore W2588227109C191093355 @default.
• W2588227109 hasConceptScore W2588227109C2776694085 @default.
• W2588227109 hasConceptScore W2588227109C2776755627 @default.
• W2588227109 hasConceptScore W2588227109C2778461978 @default.
• W2588227109 hasConceptScore W2588227109C2779429289 @default.
• W2588227109 hasConceptScore W2588227109C2779491297 @default.
• W2588227109 hasConceptScore W2588227109C2781059491 @default.
• W2588227109 hasConceptScore W2588227109C2781107101 @default.
• W2588227109 hasConceptScore W2588227109C2909962599 @default.
• W2588227109 hasConceptScore W2588227109C29730261 @default.
• W2588227109 hasConceptScore W2588227109C38180746 @default.
• W2588227109 hasConceptScore W2588227109C71924100 @default.
• W2588227109 hasLocation W25882271091 @default.
• W2588227109 hasOpenAccess W2588227109 @default.
• W2588227109 hasPrimaryLocation W25882271091 @default.
• W2588227109 isParatext "false" @default.
• W2588227109 isRetracted "false" @default.
• W2588227109 magId "2588227109" @default.
• W2588227109 workType "article" @default.